2023 Arizona Revised Statutes › Title 36 - Public Health and Safety › § 36-2608 - Reporting requirements; waiver; exceptions

36-2608.
Reporting requirements;  waiver;  exceptions
A. If a medical practitioner dispenses a controlled substance listed in section 36-2513,  36-2514,  36-2515 or 36-2516 or the rules adopted pursuant to chapter 27,  article 2 of this title,  or if a prescription for a controlled substance listed in any of those sections or naloxone hydrochloride or any other opioid antagonist that is approved by the United States food and drug administration is dispensed by a pharmacy in this state,  a health care facility in this state for outpatient use or a board-permitted nonresident pharmacy for delivery to a person residing in this state,  the medical practitioner,  health care facility or pharmacy must report the following information as applicable and as prescribed by the board by rule:
1. The name,  address,  telephone number,  prescription number and United States drug enforcement administration controlled substance registration number of the dispenser.
2. The name,  address and date of birth of the person for whom the prescription is written.
3. The name,  address,  telephone number and United States drug enforcement administration controlled substance registration number of the prescribing medical practitioner.
4. The name,  strength,  quantity,  dosage and national drug code number of the schedule II,  III,  IV or V controlled substance or naloxone hydrochloride or other opioid antagonist dispensed.
5. The date the prescription was dispensed.
6. The number of refills,  if any,  authorized by the medical practitioner.
B. Except as provided in subsection D of this section,  a dispenser must use the latest version of the standard implementation guide for prescription monitoring programs published by the American society for automation in pharmacy to report the required information.
C. The board shall allow the reporter to transmit the required information by electronic data transfer if feasible or,  if not feasible,  on reporting forms as prescribed by the board. The reporter shall submit the required information once each day.
D. A dispenser who does not have an automated recordkeeping system capable of producing an electronic report in the established format may request a waiver from electronic reporting by submitting a written request to the board. The board shall grant the request if the dispenser agrees in writing to report the data by submitting a completed universal claim form as prescribed by the board by rule.
E. The board by rule may prescribe the prescription form to be used in prescribing a schedule II,  III,  IV or V controlled substance if the board determines that this would facilitate the reporting requirements of this section.
F. The reporting requirements of this section do not apply to the following:
1. A controlled substance that is administered directly to a patient.
2. A controlled substance that is dispensed by a medical practitioner at a health care facility licensed by this state if the quantity dispensed is limited to an amount adequate to treat the patient for a maximum of seventy-two hours with not more than two seventy-two-hour cycles within any fifteen-day period.
3. A controlled substance sample.
4. The wholesale distribution of a schedule II,  III,  IV or V controlled substance. For the purposes of this paragraph,  " wholesale distribution"  has the same meaning prescribed in section 32-1981.
5. A facility that is registered by the United States drug enforcement administration as a narcotic treatment program and that is subject to the recordkeeping provisions of 21 Code of Federal Regulations section 1304.24.
G. A pharmacist who dispenses naloxone hydrochloride or another opioid antagonist to an individual pursuant to section 32-1979 shall report the information listed in subsection A,  paragraphs 1,  2,  3 and 5 of this section and the name,  strength,  quantity,  dosage and national drug code number as prescribed by the board by rule pursuant to subsection A of this section.
H. Naloxone hydrochloride or any other opioid antagonist shall not be viewable in the patient utilization report.